二次进展性多发性硬化症的经济负担:DISCOVER研究
Celia Oreja-Guevara1,2, José E Meca-Lallana3, Irene Gómez-Estévez4
1Neurology Department, CSUR Multiple Sclerosis, Hospital Universitario Clínico San Carlos, IdISCC, Planta Sexta Norte, Calle del Prof. Martín Lagos, Madrid, 28040, Spain. orejacbn@gmail.com.
BMC health services research
|April 9, 2025
概括
二次渐进性多发性硬化症 (SPMS) 给社会经济带来了巨大的负担,西班牙每年每名患者的医疗费用接近41,500欧元. 较高的成本与严重的残疾和较差的功能结果相关.
科学领域:
- 神经学 神经学
- 卫生经济学 卫生经济学
- 公共卫生 公共卫生
背景情况:
- 二次渐进性多发性硬化症 (SPMS) 显著影响患者的生活和医疗保健系统.
- 估计SPMS的综合社会经济负担对于资源分配和政策制定至关重要.
研究的目的:
- 量化与SPMS相关的直接医疗保健,直接非医疗保健和间接成本.
- 调查患者成本与其功能结果之间的关系.
主要方法:
- 一项观察性,横截面的多中心研究收集了西班牙34家医院 (2019-2020年) 的回顾性数据.
- 数据包括临床状态 (EDSS,复发,DMT),并发症,资源利用,成本和患者报告的12-24个月的结果.
- 分析了来自神经病学服务的现实世界临床实践数据.
主要成果:
- 据估计,西班牙每年每位SPMS患者的社会经济负担约为41,500欧元.
- 间接成本占50%以上 (21,400欧元),其次是直接医疗保健 (11,300欧元) 和直接非医疗保健成本 (8,800欧元).
- 较高的成本与老年,严重残疾和更差的功能结果有关.
结论:
- SPMS对医疗保健系统,患者和社会来说是一个巨大的负担.
- 医疗保健和社会政策应专注于优化SPMS护理途径.
- 建议尽量减少患者直接非医疗保健费用的自付费用.
相关概念视频
Secondary Healthcare System
1.4K
Secondary healthcare is offered by a specialist, generally in hospitals or clinics for patients referred by primary healthcare providers. It occurs when a person has an illness or injury that requires specific medical care. Secondary care is often referred to as acute care. Secondary care can range from uncomplicated care to repair a minor laceration or treat a strep throat infection to more complicated emergent care, such as treating a head injury sustained in an automobile accident. Whatever...
1.4K
Parkinson's Disease: Overview
342
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
342
Myasthenia Gravis: Overview and Treatment
1.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.0K


